Amneal Pharmaceuticals is crushing it in Q2 2026, raking in $796M in revenue and $206M in adjusted EBITDA, with EPS at 30 cents — marking their seventh straight year of growth. They’re raising their full-year outlook again and doubling down on biosimilars, set to acquire Kashiv for full integration from R&D to commercialization. With a wave of biologics losing exclusivity on the horizon, Amneal sees massive upside. Their Specialty drugs CREXONT (gaining traction as a potential first-line Parkinson’s treatment) and BREKIYA (strong uptake for migraine and cluster headaches) are flying off shelves. They’re also expanding manufacturing, including an FDA pilot program, while bouncing back from minor flooding in India. AI and automation are powering their supply chain, and the Kashiv deal is closing soon — poised to deliver big financial wins. With a laser focus on executing across all segments, Amneal is bullish on biosimilars, Specialty growth, and new pipeline partnerships.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
